- Active not recruitingPHASE3
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
This study is for people with Tuberous Sclerosis Complex (TSC) and difficult-to-treat seizures who are already taking everolimus in a related study (EXIST-3) and benefitting from it. It aims to gather long-term information on the safety of everolimus.
For: Tuberous Sclerosis ComplexUnited States · Australia · Belgium - Active not recruitingPHASE3
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
This study looks at a new type of radiation treatment called PRRT (using Lutetium-177) for certain aggressive bowel and pancreas neuroendocrine tumours. It compares this new treatment with standard care to see if it's more effective, safer, and improves patients' quality of life.
For: Neuroendocrine TumorsUnited States · Australia · China - RecruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
This study is testing a new medicine called EP0062 for advanced breast cancer. It aims to find the safest and most effective dose, both alone and with other standard treatments, for women whose cancer has specific features.
For: Hormone Receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Metastatic Breast CancerUnited States · Spain · United Kingdom - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued treatment with everolimus after completion of Study CRAD001M2304 (EXIST-3)
This study looks at the long-term safety of a medicine called everolimus for adults with a condition called tuberous sclerosis complex (TSC) who have seizures that are difficult to control. It's for people who have already been in a previous study and whose doctors think they are still benefiting from everolimus.
For: Refractory seizures associated with tuberous sclerosis complexPoland - Active not recruitingPHASE1, PHASE2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.
For: Breast Cancer · Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
This study compares a new drug called belzutifan with an existing drug, everolimus, for people with advanced kidney cancer. We want to see if belzutifan can stop the cancer from growing for longer and help people live longer than everolimus.
For: Carcinoma, Renal CellUnited States · Brazil · Canada - RecruitingPHASE3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
This study is for people with advanced ER+/HER2- breast cancer with an ESR1 gene change, whose cancer has grown despite previous treatments. It tests a new drug called elacestrant alongside an existing one, everolimus, to see if this combination works better at stopping the cancer from growing.
For: Advanced Breast Cancer · ER-positive Breast Cancer · HER2-negative Breast CancerAustria · Brazil · Czechia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
This study looks at a new drug, giredestrant, with an existing drug, everolimus, for advanced breast cancer. It compares this combination to standard hormone therapy plus everolimus, for people whose cancer has grown despite previous treatments.
For: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Germany - RecruitingPHASE2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
This study is looking at new drug combinations to treat certain types of brain tumours in children and young adults. It aims to see if combining ribociclib with either everolimus or temozolomide can help patients live longer and improve their health.
For: High Grade Glioma · Diffuse Intrinsic Pontine Glioma · Anaplastic AstrocytomaUnited States · Australia · Canada - Active not recruitingPHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
This study is testing a new combination treatment for advanced breast cancer. It combines a drug called belzutifan with fulvestrant, comparing it to standard hormone therapy. The goal is to see if this new approach is effective and safe for people whose cancer has spread and is hormone-sensitive.
For: Metastatic Breast CancerUnited States · Argentina · Canada - RecruitingPHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
This study looks at the long-term effects of a medicine called belzutifan for people with advanced cancers or cancers linked to Von Hippel-Lindau disease. It's for those already taking belzutifan in other trials. The aim is to see how long people live after starting this treatment.
For: Von Hippel-Lindau Disease · Carcinoma, Renal CellUnited States · Belgium · Canada - RecruitingPHASE3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study is for people with a type of cancer called GEP-NETs that has grown after previous treatment. It tests a new medicine, RYZ101, against standard treatments to see if it is safe and works better in stopping the cancer's growth.
For: GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor DiseaseUnited States · Belgium · Brazil - RecruitingEARLY_PHASE1
Pilot Trial for Treatment of Recurrent Glioblastoma
This early trial aims to test new, personalised treatments for people with an aggressive type of brain tumour called glioblastoma that has come back. It will check if these treatments are safe and if this type of study can be done on a larger scale.
For: Glioblastoma · Recurrent Disease · Recurrent GlioblastomaCanada - Active not recruitingPHASE2
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
This study looks at a new drug, PF-07220060, combined with fulvestrant for advanced or metastatic breast cancer. It compares this combination to standard treatments to see if it's safe and effective for people whose cancer has progressed after previous therapies.
For: Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.
For: Advanced Solid Tumors · Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States · Australia · Austria - Active not recruitingPHASE3
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
This study compares a new radiation treatment (177Lu-edotreotide PRRT) with a standard drug (Everolimus) for people with certain types of advanced neuroendocrine tumours that affect the gut or pancreas. It aims to see which treatment works better and is safer.
For: Neuroendocrine TumorsUnited States · Australia · Austria - Active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
For: Renal Cell CarcinomaUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE3
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
This study looks at adding a drug called everolimus to standard hormone therapy for women with a high risk of breast cancer returning. It aims to see if this new combination can better prevent the cancer from coming back after initial treatment.
For: Primary Non-metastatic Breast Cancer · Who Remain Disease-freeFrance - RecruitingPHASE3
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
This study is testing new medicines for a type of brain tumour called Diffuse Intrinsic Pontine Glioma (DIPG) and similar tumours (Diffuse Midline Gliomas in children and young people over 6 months old). It compares two drugs, Everolimus and ONC201, to see which works best.
For: Diffuse Intrinsic Pontine Glioma · Diffuse Midline Glioma, H3 K27M-Mutant · Diffuse Midline Glioma, H3K27-alteredDenmark · France · Spain - RecruitingNA
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
This study is looking at a new way to treat kidney transplant rejection. It focuses on a type of rejection linked to natural killer (NK) cells. Researchers want to see if a medicine called Everolimus can help prevent the body from attacking the transplanted kidney when this specific type of rejection happens.
For: Kidney Transplant Failure and RejectionFrance - RecruitingPHASE2, PHASE3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
This study compares two medicines, zanzalintinib and everolimus, for treating advanced neuroendocrine tumours. It aims to see which is more effective for people whose tumours have grown or spread despite previous treatments. This is a crucial step in finding better ways to manage this condition.
For: Pancreatic Neuroendocrine Tumor (pNET) · Extra-Pancreatic Neuroendocrine Tumor (epNET)United States · Australia · Austria - RecruitingPHASE3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
This study is testing a new medicine, PF-07248144, with an existing one, fulvestrant, for advanced breast cancer that has grown despite previous treatment. It aims to see if this combination is safe and effective.
For: Breast CancerUnited States · Australia · Belgium